SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Quiros J R)
 

Sökning: WFRF:(Quiros J R) > Metabolic perturbat...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00009974naa a2201177 4500
001oai:gup.ub.gu.se/297800
003SwePub
008240528s2021 | |||||||||||000 ||eng|
009oai:DiVA.org:umu-174900
009oai:lup.lub.lu.se:09c34782-6bfd-446b-b2b5-8bde853b96df
024a https://gup.ub.gu.se/publication/2978002 URI
024a https://doi.org/10.1002/ijc.332362 DOI
024a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1749002 URI
024a https://lup.lub.lu.se/record/09c34782-6bfd-446b-b2b5-8bde853b96df2 URI
040 a (SwePub)gud (SwePub)umud (SwePub)lu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Stepien, M.u International Agency for Research on Cancer, World Health Organization4 aut
2451 0a Metabolic perturbations prior to hepatocellular carcinoma diagnosis: Findings from a prospective observational cohort study
264 c 2020-08-28
264 1b Wiley,c 2021
520 a Hepatocellular carcinoma (HCC) development entails changes in liver metabolism. Current knowledge on metabolic perturbations in HCC is derived mostly from case-control designs, with sparse information from prospective cohorts. Our objective was to apply comprehensive metabolite profiling to detect metabolites whose serum concentrations are associated with HCC development, using biological samples from within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (>520 000 participants), where we identified 129 HCC cases matched 1:1 to controls. We conducted high-resolution untargeted liquid chromatography-mass spectrometry-based metabolomics on serum samples collected at recruitment prior to cancer diagnosis. Multivariable conditional logistic regression was applied controlling for dietary habits, alcohol consumption, smoking, body size, hepatitis infection and liver dysfunction. Corrections for multiple comparisons were applied. Of 9206 molecular features detected, 220 discriminated HCC cases from controls. Detailed feature annotation revealed 92 metabolites associated with HCC risk, of which 14 were unambiguously identified using pure reference standards. Positive HCC-risk associations were observed forN1-acetylspermidine, isatin,p-hydroxyphenyllactic acid, tyrosine, sphingosine,l,l-cyclo(leucylprolyl), glycochenodeoxycholic acid, glycocholic acid and 7-methylguanine. Inverse risk associations were observed for retinol, dehydroepiandrosterone sulfate, glycerophosphocholine, gamma-carboxyethyl hydroxychroman and creatine. Discernible differences for these metabolites were observed between cases and controls up to 10 years prior to diagnosis. Our observations highlight the diversity of metabolic perturbations involved in HCC development and replicate previous observations (metabolism of bile acids, amino acids and phospholipids) made in Asian and Scandinavian populations. These findings emphasize the role of metabolic pathways associated with steroid metabolism and immunity and specific dietary and environmental exposures in HCC development.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaper0 (SwePub)3012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicine0 (SwePub)3012 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng
653 a hepatocellular carcinoma
653 a prospective observational cohort
653 a untargeted
653 a metabolomics
653 a body-mass index
653 a cancer prevention
653 a androgen receptor
653 a alpha-tocopherol
653 a beta-carotene
653 a breast-cancer
653 a liver-disease
653 a bile-acids
653 a vitamin-e
653 a serum
653 a Oncology
653 a hepatocellular carcinoma
653 a untargeted metabolomics
700a Keski-Rahkonen, P.u International Agency for Research on Cancer, World Health Organization4 aut
700a Kiss, A.u International Agency for Research on Cancer, World Health Organization4 aut
700a Robinot, N.u International Agency for Research on Cancer, World Health Organization4 aut
700a Duarte-Salles, T.u Institut Universitari d’Investigació en Atenció Primària Jordi Gol,International Agency for Research on Cancer, World Health Organization4 aut
700a Murphy, N.u International Agency for Research on Cancer, World Health Organization4 aut
700a Perlemuter, G.u Antoine-Béclère Hospital,Inflammation, Chimiokines et Immunopathologie (Inserm Umr 996),University of Paris-Saclay4 aut
700a Viallon, V.u International Agency for Research on Cancer, World Health Organization4 aut
700a Tjonneland, A.u Danish Cancer Society4 aut
700a Rostgaard-Hansen, A. L.u Danish Cancer Society4 aut
700a Dahm, C. C.u Aarhus University4 aut
700a Overvad, K.u Aarhus University,Aalborg University Hospital4 aut
700a Boutron-Ruault, M. C.u Centre for Research in Epidemiology and Population Health (CESP),Institut Gustave Roussy4 aut
700a Mancini, F. R.u Institut Gustave Roussy,Centre for Research in Epidemiology and Population Health (CESP)4 aut
700a Mahannat-Saleh, Y.u Centre for Research in Epidemiology and Population Health (CESP),Institut Gustave Roussy4 aut
700a Aleksandrova, K.u German Institute of Human Nutrition4 aut
700a Kaaks, R.u German Cancer Research Centre4 aut
700a Kühn, Tilmanu German Cancer Research Centre4 aut0 (Swepub:lu)extLU-26
700a Trichopoulou, A.u National and Kapodistrian University of Athens,Hellenic Health Foundation, Athens4 aut
700a Karakatsani, A.u Hellenic Health Foundation, Athens,National and Kapodistrian University of Athens4 aut
700a Panico, S.u University of Naples Federico II4 aut
700a Tumino, R.u Provincial Health Authority (ASP) Ragusa4 aut
700a Palli, D.u Cancer Research and Prevention Institute (ISPO)4 aut
700a Tagliabue, G.u Istituto Nazionale dei Tumori4 aut
700a Naccarati, A.u Italian Institute for Genomic Medicine (IIGM)4 aut
700a Vermeulen, R. C. H.u Utrecht University4 aut
700a Bueno-de-Mesquita, H. B.u National Institute for Public Health and the Environment (RIVM),University Medical Center Utrecht,University of Malaya,Imperial College London4 aut
700a Weiderpass, E.u International Agency for Research on Cancer, World Health Organization4 aut
700a Skeie, G.u UiT The Arctic University of Norway, Tromsø4 aut
700a Quiros, J. R.u Public Health Directorate4 aut
700a Ardanaz, Evau Health Research Institute of Navarra (IDISNA),CIBER Epidemiology and Public Health (CIBERESP)4 aut0 (Swepub:lu)extLU-05
700a Mokoroa, O.u Biodonostia Health Research Institute,CIBER Epidemiology and Public Health (CIBERESP)4 aut
700a Sala, N.u Catalan Institute of Oncology4 aut
700a Sanchez, M. J.u University of Granada,CIBER Epidemiology and Public Health (CIBERESP),International Agency for Research on Cancer, World Health Organization4 aut
700a Huerta, J. M.u CIBER Epidemiology and Public Health (CIBERESP),Murcia Regional Health Council4 aut
700a Winkvist, Anna,d 1962u Umeå University,Umeå universitet,Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine,Avdelningen för hållbar hälsa,The Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden4 aut0 (Swepub:umu)anwi0332
700a Harlid, Sophia,d 1978-u Umeå University,Umeå universitet,Onkologi4 aut0 (Swepub:lu)mikr-sha
700a Ohlsson, Bodilu Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)kir-boh
700a Sjöberg, Klasu Lund University,Lunds universitet,Gastroenterologi,Forskargrupper vid Lunds universitet,Gastroenterology,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)medf-ksj
700a Schmidt, J. A.u University of Oxford4 aut
700a Wareham, N.u University of Cambridge4 aut
700a Khaw, K. T.u University of Cambridge4 aut
700a Ferrari, P.u International Agency for Research on Cancer, World Health Organization4 aut
700a Rothwell, J. A.u Institut Gustave Roussy,International Agency for Research on Cancer, World Health Organization4 aut
700a Gunter, M.u International Agency for Research on Cancer, World Health Organization4 aut
700a Riboli, E.u Imperial College London4 aut
700a Scalbert, A.u International Agency for Research on Cancer, World Health Organization4 aut
700a Jenab, M.4 aut
710a International Agency for Research on Cancer, World Health Organizationb Institut Universitari d’Investigació en Atenció Primària Jordi Gol4 org
773t International Journal of Cancerd : Wileyg 148:3, s. 609-625q 148:3<609-625x 0020-7136x 1097-0215
856u http://dx.doi.org/10.1002/ijc.33236y FULLTEXT
8564 8u https://gup.ub.gu.se/publication/297800
8564 8u https://doi.org/10.1002/ijc.33236
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-174900
8564 8u https://lup.lub.lu.se/record/09c34782-6bfd-446b-b2b5-8bde853b96df

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy